Nelkarmi FDA Approval: What GSK's Second Nuvalent Lung

✓ Medically reviewed | Published: | Evidence level: 1A
According to Fierce Pharma, GSK has received FDA approval for Nelkarmi, the second lung cancer medicine to come from its deal with Nuvalent. The approval reflects continued progress in precision oncology for non-small cell lung cancer driven by specific genetic alterations. Patients and clinicians should consult the official label for indications and safety details.
📅 Published:
✓ Reviewed by iMedic Medical Editorial Team
📄 Oncology

Quick Facts

Approving agency
US FDA
Developer deal
GSK and Nuvalent
Cancer type
Lung cancer
Approach
Targeted therapy

Why do targeted therapies matter in lung cancer?

Quick answer: Targeted therapies block specific genetic drivers of tumor growth, which can control disease more effectively and with different side effects than conventional chemotherapy in selected patients.

Lung cancer remains the leading cause of cancer death worldwide, according to the World Health Organization. A meaningful subset of non-small cell lung cancer (NSCLC) is driven by specific genetic alterations, such as changes involving the ALK, ROS1, EGFR or other genes. Testing tumor tissue for these alterations, known as biomarker or molecular testing, allows clinicians to match patients to drugs that block the abnormal protein fueling the cancer.

Over the past decade, oral kinase inhibitors have changed the outlook for many of these patients, often producing longer disease control than chemotherapy alone. A recurring challenge, however, is acquired resistance: tumors develop new mutations that let them evade a drug, and brain metastases can limit options. Next-generation inhibitors are designed to address these problems.

What does the Nelkarmi approval signal?

Quick answer: It signals that GSK's Nuvalent partnership is delivering a second approved lung cancer product, expanding options in precision oncology.

Fierce Pharma reports that Nelkarmi is the second lung cancer drug GSK has brought to approval from its Nuvalent agreement. Nuvalent's research has centered on kinase inhibitors for oncogene-driven lung cancers, with an emphasis on activity against resistance mutations and on reaching the brain. Readers should consult the FDA label for the exact indication, the patient population and the data supporting approval.

For patients, the practical message is the importance of comprehensive biomarker testing at diagnosis and at progression. A newly approved therapy only helps if the tumor's genetic profile is known. Side effects of kinase inhibitors can include liver enzyme changes, swelling, fatigue and gastrointestinal symptoms, and treatment decisions should be made with an oncologist who can weigh benefit, safety and prior therapy history.

Frequently Asked Questions

Eligibility depends on the FDA-approved indication, typically tied to a specific genetic alteration found on tumor testing and prior treatment history. An oncologist can confirm whether a patient qualifies.

Testing identifies genetic drivers of the tumor so patients can receive matched targeted therapy, which may offer better disease control than chemotherapy for some people.

The FDA-approved prescribing information lists the official indication, dosing and safety warnings; discuss it with your care team.

References

  1. Fierce Pharma. GSK scores FDA approval for Nelkarmi, its 2nd lung cancer drug from Nuvalent deal. November 2026.
  2. World Health Organization. Lung cancer fact sheet.